Allogene Therapeutics, Inc.
ALLO-329
Autoimmune Disease
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ALLO-329 in Autoimmune Disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Initial observations at these early low dose levels show signs of clinical activity and favorable tolerability.”